News

Vaccine Testing in Children

Kimberly Redmond | Equities.com |

Newly-released data from an ongoing study of the COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) shows the two-dose shot offered high levels of protection for at least six months after administration.

On Thursday, the companies released updated topline results from their Phase 3 trial, which found the vaccine had 91.3% efficacy against the virus, and said they plan to apply for full approval from the US Food and Drug Administration. Currently, all of the vaccines in use in the US have only Emergency Use Authorization (EUA) from the FDA.


AP News | Equities.com |

Pfizer announced Wednesday that its COVID-19 vaccine is safe and strongly protective in kids as young as 12, a step toward possibly beginning shots in this age group before they head back to school in the fall.

Most COVID-19 vaccines being rolled out worldwide are for adults, who are at higher risk from the coronavirus. Pfizer’s vaccine is authorized for ages 16 and older. But vaccinating children of all ages will be critical to stopping the pandemic — and helping schools, at least the upper grades, start to look a little more normal after months of disruption.


AP News | Equities.com |

The 9-year-old twins didn’t flinch as each received test doses of Pfizer’s COVID-19 vaccine -- and then a sparkly bandage to cover the spot.

“Sparkles make everything better,” declared Marisol Gerardo as she hopped off an exam table at Duke University to make way for her sister Alejandra.

Researchers in the U.S. and abroad are beginning to test younger and younger kids to make sure COVID-19 vaccines are safe and work for each age. The first shots are going to adults who are most at risk from the coronavirus, but ending the pandemic will require vaccinating children too.